VIRTUAL PRESIDENTIAL SYMPOSIUM

Topic: Peri-operative Adjuvant IO or TKIs Therapy for Resected NSCLC
Speaker: Masahiro Tsuboi, Japan
Dr Masahiro Tsuboi is a director of Division of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan, and a visiting assistant professor, Department of Surgery, Yokohama City University Graduate school of Medicine, Yokohama, Japan

Dr Tsuboi is a past board director of International Association for the Study of Lung Cancer (IASLC), a past chair of the Lung Cancer Surgical Study Group (LCSSG) of the Japan Clinical Oncology Group (JCOG), and a past board director of World Association of Bronchology and Interventional Pulmonology (WABIP).

Dr Tsuboi is involved in numerous perioperative adjuvant and surgical clinical trials as a primary investigator or a member of the study steering committee. He is a co-primary investigator for the ADAURA study, which is a randomized phase III study with osimertinib as postoperative adjuvant therapy in patients with stage IB–IIIA EGFR mutation positive non-small cell lung cancer, with Prof. R. Herbst and Prof. YL Wu.

Other professional activities:
2001 - present | Councilor, Japanese Association of Chest Surgery
2002 - present | Councilor, Japan Lung Cancer Society
2004 - present | Councilor, Japan Society of Respiratory Endoscopy
2014 - present | Councilor, Japanese Association of Esophagobronchology

Specialty and Research Fields of Interest:
Clinical trials for Thoracic Malignancies
Surgical Treatment for Thoracic Malignancies
Surgical and Medical Oncology for Thoracic Malignancies
Combined Modality Treatment for Lung Cancer & mesothelioma
Video-Assisted Thoracic Surgery
Endoscopic diagnosis for Thoracic Malignancies (EBUS, OCT)
Surgical Treatment for Myasthenia Gravis

Topic: COVID-19 in Thoracic Malignancies
Speaker: Marina Garassino, Italy
Dr Marina Chiara Garassino is the Chief of the Thoracic Oncology Unit at Istituto Nazionale dei Tumori, Milan, Italy. She leads the strategy for clinical and translational research in advanced and locally advanced NSCLC, SCLC, mesothelioma and thymic malignancies. Istituto Nazionale dei Tumori in Milan is the most important Comprehensive Cancer Center in Italy, and one of the most important in Europe.

As a medical oncologist, she has done research in precision medicine and in immuno-oncology.

Her main research interests have been: NSCLC, SCLC, mesothelioma and development of biomarkers.

She has contributed to over 160 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology. She has delivered many presentations at international congresses, including AACR, ASCO, ECCO, ESMO, WCLC.

Her education includes a degree and further specialization in Medical Oncology at Università degli Studi, in Milan. She completed her training with an ESMO Clinical fellowship in 2009 at Christie's Hospital in Manchester (UK). She was a member of the EMA SAG (Scientific Advisory Group). She achieved a Master Degree in Oncology management at University of Economics “Luigi Bocconi”.

Dr Garassino is serving on several ESMO Committees (Public Policy extended Committee, Press Committee, Women for Oncology Committee, Lung Cancer faculty, Membership Committee) and as Chair of the National Societies Committee, from 2019.

She is the founder and president of Women for Oncology Italy.

Topic: A Lung Cancer Patient's Manifesto for Modernizing Clinical Trials
Speaker: Janet Freeman-Daily, USA
Janet Freeman-Daily, MS, Eng, is a retired aerospace systems engineer (trained at MIT and Caltech), freelance writer, speaker, and metastatic lung cancer patient/activist. She was diagnosed with advanced non-small cell lung cancer in May 2011, and progressed to stage 4 despite two lines of chemo-radiation. Fortunately, she learned about biomarker testing and clinical trials from other patients in online lung cancer communities. Thanks to a targeted therapy clinical trial, she has had no sign of cancer on scans since January 2012. Her focus is now on translating the experience and science of cancer for others. She writes an award-winning blog, cofounded and co-manages The ROS1ders, serves on staff for the IASLC STARS program, collaborates with lung cancer patient and advocacy organizations, and speaks as a research advocate at international oncology conferences, cancer research centers, biomedical and pharmaceutical companies, and government agencies. Her advocacy work focuses on ROS1 cancer, lung cancer, patient-centered outcomes, modernizing clinical trials, access to biomarker testing, data sharing, shared decision making, and goals of care.

Abstract: ORIENT-11: Sintilimab + Pemetrexed + Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC
Speaker: Zhang Li, China
Professor Li Zhang is Professor of Medical Oncology, Director of Medical Oncology Department and Phase I Unit of Sun Yat-Sen University Cancer Centre (SYSUCC), Deputy Director of Lung Cancer Research Centre of SYSU. He is also the member of ASCO, CSCO, ESMO, IASLC, MASCC and Board of Directors of MASCC, Member of communication committee of IASLC. He completed training as a visiting fellow at the MD Anderson Cancer Centre; Fox Chase Cancer Centre, USA and Institut Gustave Roussy, Paris, France. Professor Zhang has published more than 200 clinical papers in top-tier journals like: Lancet, Journal of Clinical Oncology, Lancet Oncology, JAMA Oncology, Annals of Oncology, JTO.

Discussant: Misako Nagasaka, USA
Dr. Misako Nagasaka is a thoracic oncologist and a clinical investigator at the Karmanos Cancer Institute, located in Detroit, Michigan. She is also an assistant professor at the Wayne State University School of Medicine, Department of Oncology. Her clinical and research interests are in molecular targeted therapy and immunotherapy in thoracic and head and neck malignancies, with a special focus in medical ethics. She serves as the site principal investigator (PI) for over 20 active clinical trials and enjoys collaborating with other PIs across the country and around the world.

Abstract: Phase 3 Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK)–Positive NSCLC Patients: eXalt3
Speaker: Leora Horn, USA
Dr. Horn is an Associate Professor of Medicine and the Clinical Director of the Thoracic Oncology Research Program at Vanderbilt Ingram Cancer Center (VICC) in Nashville TN. She is also the Assistant Vice Chairman for Faculty Development at Vanderbilt University Medical Center. Her clinical practice focuses on the care of patients with lung cancer. She is an active member of the Eastern Cooperative Oncology Group, International Association for the Study of Lung Cancer and the American Society of Clinical Oncology. She has over 1000 publications including in the New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology. In the last five years, she has been among the top 5 in accrual to clinical trials at VICC where she has a focus on clinical trials with targeted therapies and immunotherapy as well as small cell lung cancer.

Discussant: Christine Lovly, USA
Dr. Christine Lovly is a physician-scientist with a special interest in thoracic malignancies. Dr. Lovly's clinical practice focuses primarily on the care of patients with lung cancer. Her laboratory research is directed at understanding and developing improved therapeutic strategies for specific clinically relevant molecular subsets of lung cancer. She is the author of several peer-reviewed scientific manuscripts, and she is an active member in the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), and the American Association for Cancer Research (AACR).

Abstract: First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743
Speaker: Paul Baas, Netherlands
Dr Paul Baas gained his medical degree in 1986 from the University of Amsterdam and trained for chest physician at the Free University. Currently, Dr Baas is head of the department of Thoracic Oncology at the Netherlands Cancer Institute in Amsterdam. He holds a PhD degree in Applied Medicine at the University of Amsterdam and has been appointed as a Professor in Thoracic Oncology at the University Hospital of Leiden. He has published over 250 peer reviewed papers and is involved in the several cancer research groups like the, ETOP, EORTC and ESMO. Since 1992 he focused on translational research as part of studies initiated in his clinic.

Discussant: Dean Fennell, UK
Dean Fennell is Professor & consultant in Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Programme based at the University of Leicester and University Hospitals of Leicester in the UK. He is an internationally recognised key opinion leader, clinical investigator and translational researcher with a focus on mesothelioma. He has led several investigator-initiated trials from phase 1 through to phase III. Prof. Fennell is member of the IASLC mesothelioma taskforce, steering committee for the British Lung Foundation mesothelioma research network, past president of the International Mesothelioma Interest Group, and co-author of the UK BTS, and European (ESMO, ERS) mesothelioma treatment guidelines. He is currently the Leicester lead for the ground breaking CRUK TraceRx/Darwin studies in lung cancer and BLF supported MEDUSA (mesothelioma) evolution studies. Prof. Fennell held two prestigious CRUK clinician scientist and MRC doctoral fellowships. He originally trained in pharmacology (1st class) and medicine at University College London where he was awarded several prizes. He completed medical training in the London Golden circuit (Hammersmith, Brompton, Guy's, St Thomas's), and completed his specialist training at Barts Hospital. Prof. Fennell has published over 100 peer reviewed articles in journals including The Lancet, Lancet Oncology, New England Journal of Medicine, Nature, Nature Reviews Cancer, and Proceedings of the National Academy of Sciences.